Active Ingredient History

  • Now
Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). It also appears to have had a statistically significant effect of reducing breast cancer in women according to a study published in The Journal of the National Cancer Institute.   Wikipedia

  • SMILES: Oc1ccc2[C@H]([C@H](CCc2c1)c3ccccc3)c4ccc(OCCN5CCCC5)cc4
  • Mol. Mass: 413.56
  • ALogP: 5.73
  • ChEMBL Molecule:
More Chemistry
cis-1r-(4'-pyrrolidinoethoxyphenyl)-2s-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt | (-)-cis-5,6,7,8-tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol | cp 336156 | cp-336156 | cp-336,156 | fablyn | las estrogen receptor modulator | lasofoxifene | lasofoxifene hydrochloride | lasofoxifene tartrate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue